Adlai Nortye Group (ANL) vs Cullinan Therapeutics (CGEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 796.5% versus a gain of 139.7%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $950.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | CGEM |
|---|---|---|
| Share price | $15.51 | $15.46 |
| Market cap | $998.81M | $950.14M |
| 1-day change | +10.39% | -1.09% |
| YTD return | +992.25% | +49.37% |
| 1-year return | +796.53% | +139.69% |
| 5-year return | — | -38.16% |
| EPS (TTM) | $-0.66 | $-3.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $23.19 |
| 52-week low | $0.879 | $6.50 |
| Distance from 52-week high | -10.09% | -33.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +116.36% |
| Average volume | 187.30K | 871.08K |
| Shares outstanding | 58.73M | 61.46M |
| Employees | 109 | 109 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed CGEM by 656.8 percentage points over the past year.
- The two companies sit in different sectors: Adlai Nortye Group in Healthcare and Cullinan Therapeutics in Health Care.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
ANL vs CGEM FAQ
Which is bigger, Adlai Nortye Group or Cullinan Therapeutics?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $950.14M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, ANL or CGEM?
ANL returned +796.53% over the past 12 months, compared with +139.69% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Cullinan Therapeutics in the same industry?
No. Adlai Nortye Group is in the Healthcare sector, while Cullinan Therapeutics is in Health Care.